Intraocular lens guidance
This article was originally published in The Gray Sheet
Executive Summary
Clinical studies comparing an investigational IOL to a historical control should have a minimum of 300 subjects, while certain modifications to approved devices would require 100 subjects (1"The Gray Sheet," July 26, p. 6), according to the agency's draft "Intraocular Lens Guidance." Comments are due by Jan. 12, 2000
You may also be interested in...
Revised IOL Guidance Requires 100-Patient Study For Some Design Changes
"Level B" modifications to intraocular lenses (IOLs) would require a 100-subject confirmatory study in addition to preclinical data, under FDA's draft "Intraocular Lens Guidance Document" posted July 16 on the agency's website.
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.